Stay updated on AbbVie Press Releases

Sign up to get notified when there's something new on the AbbVie Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AbbVie Press Releases page

  1. Check
    3 days ago
    Change Detected
    Summary
    AbbVie has added new video content highlighting employee experiences with migraine and the emotional impact of chronic lymphocytic leukemia (CLL), while removing information about the upcoming Migraine Career Catalyst Award contest and various tweets and news updates.
    Difference
    42%
    Check dated 2024-09-04T04:31:24.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    AbbVie has awarded scholarships to 45 U.S. students with chronic immune-mediated diseases and introduced a new skin hydration product, while the deadline for the AbbVie Migraine Career Catalyst Award contest is approaching.
    Difference
    100%
    Check dated 2024-08-28T02:17:17.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The European Commission has granted a second indication approval for TEPKINLY® (epcoritamab) for treating adults with relapsed/refractory follicular lymphoma, marking a significant development in blood cancer treatment.
    Difference
    63%
    Check dated 2024-08-21T00:03:13.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The AbbVie Migraine Career Catalyst Award™ contest is nearing its entry deadline, with one month left to participate, while a previous post about ulcerative colitis has been removed.
    Difference
    16%
    Check dated 2024-08-13T23:07:37.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    AbbVie has completed the acquisition of Cerevel Therapeutics as of August 1, 2024, marking a significant development in their portfolio, while the previous report on their second-quarter financial results from July 25, 2024, has been removed.
    Difference
    66%
    Check dated 2024-08-06T22:09:17.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    On July 30, 2024, Allergan Aesthetics is celebrating the Second Annual JUVÉDERM® Day, highlighting their commitment to accelerating the development of medicines and improving care for patients with inflammatory bowel disease (IBD).
    Difference
    68%
    Check dated 2024-07-30T22:07:15.000Z thumbnail image

Stay in the know with updates to AbbVie Press Releases

Enter your email address, and we'll notify you when there's something new on the AbbVie Press Releases page.